Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 28, 2023
Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD
Jonathan C Roberts, Pamela A Christopherson, Michael D Tarantino, et al.
Therapeutic Advances in Hematology
|
October 23, 2023
Rilzabrutinib <i>versus</i> placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
David J Kuter, James B Bussel, Waleed Ghanima, et al.
Seminars in Hematology
|
April 9, 2004
Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK
B M Ewenstein, P Collins, M D Tarantino, et al.
The Journal of Pediatrics
|
May 2, 2006
Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children
Michael D Tarantino, Guy Young, Salvatore J Bertolone, et al.
American Journal of Hematology
|
February 19, 2021
Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination
Eun-Ju Lee, Douglas B Cines, Terry Gernsheimer, et al.
Lancet (London, England)
|
April 23, 2016
Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study
Michael D Tarantino, James B Bussel, Victor S Blanchette, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2004
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
M D Tarantino, P W Collins, C R M Hay, et al.
American Journal of Hematology
|
January 23, 2025
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
Nichola Cooper, A J Gerard Jansen, Robert Bird, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2004
Consensus recommendations for use of central venous access devices in haemophilia
B M Ewenstein, L A Valentino, J M Journeycake, et al.
Blood
|
September 29, 2021
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
Eun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
November 28, 2023
Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD
Jonathan C Roberts, Pamela A Christopherson, Michael D Tarantino, et al.
Therapeutic Advances in Hematology
|
October 23, 2023
Rilzabrutinib <i>versus</i> placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
David J Kuter, James B Bussel, Waleed Ghanima, et al.
Seminars in Hematology
|
April 9, 2004
Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK
B M Ewenstein, P Collins, M D Tarantino, et al.
The Journal of Pediatrics
|
May 2, 2006
Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children
Michael D Tarantino, Guy Young, Salvatore J Bertolone, et al.
American Journal of Hematology
|
February 19, 2021
Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination
Eun-Ju Lee, Douglas B Cines, Terry Gernsheimer, et al.
Lancet (London, England)
|
April 23, 2016
Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study
Michael D Tarantino, James B Bussel, Victor S Blanchette, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2004
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
M D Tarantino, P W Collins, C R M Hay, et al.
American Journal of Hematology
|
January 23, 2025
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
Nichola Cooper, A J Gerard Jansen, Robert Bird, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia
|
September 11, 2004
Consensus recommendations for use of central venous access devices in haemophilia
B M Ewenstein, L A Valentino, J M Journeycake, et al.
Blood
|
September 29, 2021
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
Eun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, et al.
Page
of 11